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Abstract 
S100A6 is a small EF-hand calcium- and zinc-binding protein involved in the regulation of cell proliferation 
and cytoskeletal dynamics. It is overexpressed in neurodegenerative disorders and a proposed marker for 
Amyotrophic Lateral Sclerosis (ALS). Following recent reports of amyloid formation by S100 proteins, we 
investigated the aggregation properties of S100A6. Computational analysis using aggregation predictors 
Waltz and Zyggregator revealed increased propensity within S100A6 helices HI and HIV. Subsequent 
analysis of Thioflavin-T binding kinetics under acidic conditions elicited a very fast process with no lag 
phase and extensive formation of aggregates and stacked fibrils as observed by electron microscopy. Ca2+ 
exerted an inhibitory effect on the aggregation kinetics, which could be reverted upon chelation. An FT-
IR investigation of the early conformational changes occurring under these conditions showed that Ca2+ 
promotes anti-parallel β-sheet conformations that repress fibrillation. At pH 7, Ca2+ rendered the fibril 
formation kinetics slower: time-resolved imaging showed that fibril formation is highly suppressed, with 
aggregates forming instead. In the absence of metals an extensive network of fibrils is formed. S100A6 
oligomers, but not fibrils, were found to be cytotoxic, decreasing cell viability by up to 40%. This effect 
was not observed when the aggregates were formed in the presence of Ca2+. Interestingly, native S1006 
seeds SOD1 aggregation, shortening its nucleation process. This suggests a cross-talk between these two 
proteins involved in ALS. Overall, these results put forward novel roles for S100 proteins, whose metal-
modulated aggregation propensity may be a key aspect in their physiology and function.  
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Introduction 
S100 proteins comprise a family of EF-hand calcium-binding proteins. They represent central regulators 
involved in cell cycle control, cell growth, differentiation, and motility in vertebrates. In humans, 21 
different S100 paralogs are expressed (1). These proteins have organ- and tissue-specific expression 
patterns, and their biological activity is modulated by different metal ions, namely calcium (Ca2+), zinc 
(Zn2+), and copper (Cu2+). Metal ion binding to S100 proteins regulates conformation and, in some 
instances, oligomerization of S100 dimers into higher order oligomers (2, 3). A common feature in S100 
proteins is Ca2+ binding via EF-hand motifs which triggers the exposure of an inter-helical hydrophobic 
protein interaction site (1). This allows binding and regulation of different signaling molecules translating 
the Ca2+ signal into a cellular response (4, 5). Some family members also bind Zn2+ and Cu2+ at secondary 
binding sites with high affinity, and the binding of these metals is usually associated to subtle 
conformational changes (2).  
The remarkable conformational plasticity of S100 proteins and the regulatory capacity of metal ions was 
recently further extended by the report that the proinflammatory S100A8/A9 heterodimer forms amyloid 
deposits. These were found in prostatic inclusions called corpora amylacea from cancer patients, and 
protein deposition in vitro was facilitated by Ca2+ and Zn2+ (6). Clearly, protein deposition phenomena are 
becoming increasingly relevant also in cancer (7,–, 9). This finding opened the question whether other 
S100 proteins are capable to form amyloids too and whether such amyloids are involved in other diseases 
as well. Most interestingly, several S100 proteins have been reported to occur at largely elevated levels 
in neurodegenerative disorders (10,–,13).  
Underlining the importance of S100 signaling, a number of S100 proteins show altered expression levels 
in cancer and neurodegenerative, inflammatory, and auto-immune diseases (14). A paradigmatic example 
is S100A6, which regulates cell proliferation, cytoskeletal dynamics and tumorigenesis (15) in response to 
Ca2+ binding. This protein is overexpressed in Alzheimer disease (AD)2 (10, 11) and Amyotrophic Lateral 
Sclerosis (ALS), a disease characterized by progressive degeneration of motor neurons. In ALS patients, 
S100A6 is largely overexpressed in reactive astrocytes located in the brainstem and spinal cord, 
surrounding impaired motor neuron axons (11). In turn, these ALS-affected neurons contain cytoplasmic 
aggregates of Cu/Zn Superoxide Dismutase (SOD1), which are ubiquitous disease indicators (16). For this 
reason, S100A6 has been proposed as a marker for ALS (17). Also, in AD, S100A6 is up-regulated in the 
brain white matter as well as in gray matter astrocytes surrounding the Aβ senile plaques, both in human 
patients and mouse models (10).  
Following these relationships, we here report the identification and characterization of S100A6 as an 
amyloidogenic protein, and we undertake a detailed characterization of the role of Ca2+ as a modulator of 
fibril assembly, morphology and structural properties. The biophysical findings are framed in respect to 
the possible biological implications of this finding, through the analysis of the effect of metal ions on the 
cytotoxicity of amyloids and in respect to amyloid cross seeding with SOD1.  
MATERIALS AND METHODS 
Chemicals and Proteins 
All reagents were of the highest grade commercially available. Thioflavin T was obtained from Sigma. Hen 
egg white lysozyme was obtained from Fluka. A Chelex resin (Bio-Rad) was used to remove contaminant 
trace metals from all solutions. S100A6 was expressed and purified to homogeneity using reported 
protocols (18). SOD1 expression, and purification were performed as in Ref. 19 and preparation of the 
apo-form as in Ref. 20. Protein quantification was made using Bradford's method (21).  
Amyloidogenic Propensity Analysis 
The amyloidogenic propensity of S100A6 at pH 7 was computed using the Waltz (22) and Zyggregator (23, 
24) web servers.  
S100A6 Aggregation Assays 
Amyloidogenesis and fibril formation assays were performed as described previously (25). Briefly, S100A6 
was diluted into either 50 mM glycine, pH 2.5, or 50 mM Tris, pH 7. Centrifugation at 12,000 × g for 10 
min at 4 °C removed any insoluble material before aggregation assays. Final S100A6 concentration was 3 
mg/ml (295 μM). When required, a 10-fold molar excess of CaCl2 or ZnCl2 (2.9 mM) was added. Amyloid 
formation was promoted by quiescent incubation at 57 °C (pH 2.5) or at 37 °C under 1000 rpm orbital 
agitation (pH 7). Lysozyme amyloids were generated by incubating 10 mg/ml protein in 50 mM glycine pH 
2.5 at 57 °C, as described previously (26).  
Thioflavin-T Fluorescence 
The ThT fluorescence assay for the detection of amyloid was performed as described previously (26). At 
different time points, 15 μg of S100A6 or 50 μg of lysozyme were diluted in buffer and incubated under 
stirring for 2 min at 25 °C. Fluorescence (482 nm) was recorded with a Cary Varian Eclipse instrument 
upon excitation at 440 nm using a PMT voltage of 600 V and excitation and emission slits of 10 nm.  
Circular Dichroism (CD) Spectroscopy 
CD experiments were performed using a Jasco J-815 spectropolarimeter equipped with a Peltier-
controlled thermostated cell support. Far UV CD spectra and 1 °C/min thermal denaturation curves (as 
reported by the CD at 222 nm) were recorded for 0.1 mg/ml S100A6 (9.8 μM) in either 50 mM KPi pH 7 or 
50 mM glycine, pH 2.5. Spectra were deconvoluted with CDNN 2.1.  
Dynamic Light Scattering 
The mean light scattering intensity variations were determined with a Malvern Instruments Zetasizer 
Nano ZS instrument. Backscattered 633 nm laser light from fifteen 10 s accumulations was averaged to 
retrieve light scattering intensity and average particle size from the intensity distribution using the 
Malvern Instruments DTS software and a multimodal fit with quadratic weighting and 0.01 regulariser.  
Transmission Electron Microscopy 
For visualization by TEM, 5-μl sample aliquots were absorbed to carbon-coated collodion film supported 
on 400-mesh copper grids, and negatively stained with 1% uranyl acetate. The grids were exhaustively 
visualized with a Jeol microscope (JEM-1400), operated at 80 kV.  
ATR FT-IR Spectroscopy 
The secondary structure of apo and Ca2+-S100A6 was monitored during amyloid formation assays at pH 
2.5 by ATR FT-IR measurements performed in a Bruker IFS 66/S spectrometer equipped with a MCT 
detector and a thermostatized Harrick BioATR II cell. The spectrometer was set to 1 min accumulation 
time, 12 mm aperture, 20 kHz scanner velocity, and 4 cm−1 spectral resolution. Band assignments were 
based on typical absorption regions for specific secondary structure elements (27).  
Cytotoxicity 
The cytotoxicity of S100A6 toward human neuroblastoma SH-SY5Y cells was assessed by the reduction of 
the chromogenic electron acceptor WST-1 (Roche) (28). Cells were cultured in DMEM supplemented with 
10% (v/v) FBS and antibiotics in a 5% CO2 humidified atmosphere at 37 °C. After seeding in 96-well plates 
(104 cells/well), cells were grown overnight and incubated with 5 μM S100A6 in 100 μl FBS-free medium 
during 48 h. Then, 10 μl of WST-1 was added and 4 h later absorbance at 450 nm was read with a 
Labsystem Multiscan RC. Cell viability was normalized to the reading obtained with cells incubated 
without S100A6. Statistical differences were assessed with double-tailed, two sample unequal variance 
Student's t test.  
Dot-blot Analysis 
The reactivity of S100A6 oligomers against conformation-dependent antibodies was carried out in a dot-
blot analysis as described in Ref. 29 using the anti-amyloid fibrils OC antibody (AB2286 Merck Millipore) 
and the A11 anti amyloid oligomer antibody (AB9234 Merck Millipore).  
SOD1-S100A6 Cross-seeding 
For assessing the effect of S100A6 in SOD amyloidogenesis, 50 μM apo SOD1 was incubated in 50 mM 
Tris, pH 7.3, 5 mM TCEP, and 100 μM ThT at 37 °C with and without 2% native apo S100A6 (1 μM) in black 
96-well plates (Nunc FluoroNunc). One (1/8 in) teflon bead was added, and the plate was agitated at 600 
rpm during incubation. Real time ThT fluorescence (480 nm) was recorded using a BMG Fluostar Optima 
fluorescence plate reader upon excitation at 440 nm. Curve analysis and lag time determination was 
carried out as described in Ref. 30.  
RESULTS 
S100A6 Hydrophobic Core Has Amyloidogenic Propensity 
The S100A6 primary sequence was analyzed for amyloid-prone segments using two complementary 
computational algorithms: Waltz (22) and Zyggregator (23, 24). Both algorithms provide position-specific 
scores, which can be used to identify amyloidogenic hot spots in the sequence. Whereas Waltz relies on 
a combination of amyloid-prone sequence pattern recognition based on physicochemical properties and 
homology modeling, Zyggregator correlates sequence information with experimental aggregation rate 
changes upon mutation and polypeptide physicochemical properties. Both algorithms predict significant 
aggregation prone regions in helices HI (residues 11–18) and HIV (residues 71–82), within the hydrophobic 
core of S100A6 (Fig. 1). The regions with significant scores identified by Waltz (Fig. 1, gray bars) indeed 
correspond to regions with high Zyggregator scores (Zagg). Noteworthy, Zagg scores for S100A6 have a 
magnitude similar to those for Aβ1–42, the major aggregating peptide involved in AD (23). Altogether, these 
results suggest that S100A6 comprises aggregation prone segments, which may trigger amyloid fibril 
formation.  
 
 
S100A6 Forms Amyloid-like Fibrils 
We then carried out an exploratory analysis of amyloid formation by S100A6 using conditions known to 
induce fibril formation in the well-established model lysozyme, which was used as a positive control. 
Therefore, under acidic conditions and high temperature (pH 2.5 and 57 °C), we observed a very fast 
buildup of S100A6 ThT-reactive species, which developed into fibrils after 10 days of incubation (Fig. 2). 
The formation of lysozyme fibrils under these experimental conditions served as a reference to assess 
S100A6 amyloid formation in a reasonable time frame. Interestingly, the sigmoidal shape of the 
aggregation kinetic profile typical for lysozyme was not observed for S100A6 which was rather concave-
like (30) (Fig. 2A). The absence of a lag phase reflects an instantaneous nucleation process and suggests a 
high propensity of S100A6 to form directly growth-nuclei from its soluble conformation. Structural 
analysis by far-UV CD showed that S100A6 is not unfolded neither at acidic pH (of 2.5) nor at higher 
temperature (of 57 °C), thus clearly ruling out that aggregate formation is triggered from unfolded protein. 
Nevertheless, acidic conditions resulted in a conformation which retains its compactness, but has an 
altered network of interactions which results in a decreased α-helical content with a corresponding 
increase in β-sheet structures (∼4%). In fact, ultrastructural analysis by transmission electron microscopy 
(TEM) corroborated the presence of S100A6 fibrillar oligomers and protofilaments (Fig. 2, B and C). The 
fibrillar structures formed at pH 2.5 after 28 days were polymorphic and fibrils with different widths were 
observed: 4–5 nm wide fibrils (black arrow, Fig. 2B), 15 nm wide fibrils (black arrowhead, Fig. 2B), and 
several other thicker fibrils. Thick fibrils consisting of several smaller fibrils with 4–5 nm width were 
observed (white arrows, Fig. 2B). The long 4–5 nm wide protofibrils might undergo lateral association and 
represent building blocks of the larger fibrils. Nevertheless, considering the observed kinetic profile, such 
a mechanism would have a minor contribution to the overall process. In other cases, it is suggested that 
mature fibrils are instead produced by longitudinal growth of full-width species (31, 32). Indeed, this 
pathway might also apply for the formation of S100A6 fibrils since thick but short structures are observed 
(see e.g. white arrow, Fig. 2B). Furthermore, a detailed analysis of the TEM image revealed the assembly 
of structures with ∼15 nm of width, into an already partially formed fibril (Fig. 2C). Thus, it is possible that 
under the chosen conditions both mechanisms play a critical role during S100A6 fibril formation.  
 
 
Ca2+ Modulates Aggregation and Induces Structural Changes at Early Phases of Fibril Formation  
Because S100A6 is a Ca2+- and Zn2+-binding protein, we have subsequently investigated the 
conformational changes occurring at the earliest stages of S100A6 aggregation, and the effect of these 
metal ions on this process. We started by using dynamic light scattering to investigate the aggregation of 
S100A6, in the presence and absence of Ca2+ (Fig. 3A) No lag phase was observed and light scattering 
aggregates were formed up to reaching a plateau, irrespective of the presence of Ca2+. We then moved 
to investigate the ThT binding properties of these S100A6 aggregates (Fig. 3B). The results showed that 
aggregates formed starting from apo S100A6 are ThT reactive from the early stages of the aggregation 
process. However, the presence of metal ions resulted in aggregates with different ThT-binding behaviors: 
whereas Zn2+ had a negligible effect, Ca2+ repressed ThT-binding (Fig. 3B). The combination of light 
scattering and ThT-binding data suggests that Ca2+ induces the formation of aggregates that are not 
amyloidogenic and do not bind ThT. However, the possibility that Ca2+ exerts an inhibitory effect on the 
fibrillation process cannot be ruled out at this stage. Whatever the scenario, the fact is that Ca2+ modulates 
S100A6 aggregation. Accordingly, addition of EDTA to chelate Ca2+ and revert S100A6 into its apo form 
promptly restored the formation of ThT-positive species (Fig. 3B, arrow). An investigation of the reactivity 
of these oligomeric species against conformational antibodies indicated no interaction toward the anti-
amyloid fibrils antibody and very weak reactivity toward the amyloid oligomer. The structural differences 
between the apo and Ca2+-bound S100A6 conformers produced under these acidic conditions and high 
temperature were investigated using Fourier transform infrared (FT-IR) spectroscopy. The amide I region 
of the infrared spectrum (1600–1700 cm−1) provides quantitative information on secondary structure, 
being especially sensitive to β-sheet conformations (Fig. 3C). A direct comparison of the amide I band in 
the presence and in the absence of Ca2+ at identical incubation times (∼2 h) revealed significant structural 
differences. During the incubation in the presence of Ca2+ two spectral features developed: a local 
maximum at 1625 cm−1 and a shoulder at 1690 cm−1, which are very prominent in the difference spectrum 
(Fig. 3D). This combination of bands is characteristic of an anti-parallel β-sheet conformation, indicative 
of oligomeric species structurally distinct from fibrils (33). This observation is in agreement with the 
residual ThT binding observed in the presence of Ca2+ (Fig. 3B). A negative band at 1650 cm−1 is also 
observed in the difference spectrum, indicative of a decrease in α-helix content in the Ca2+-bound form. 
Altogether, these results show that binding of Ca2+ to S100A6 results in the formation of aggregated 
species which are off-pathway in respect to amyloid fibril formation.  
 
S100A6 Fibrillates under Physiological Conditions 
The formation of S100A6 amyloid-like fibrils was further investigated at physiological conditions (pH 7 and 
37 °C). As anticipated, the process of S100A6 aggregation at neutral pH was much slower, and proceeded 
via a sharper sigmoid-type transition (Fig. 4A). The absence of an evident lag phase suggests that the 
formation of the aggregation-nuclei readily takes place from the soluble conformers. In contrast, the Ca2+-
bound S100A6 conformers are less prone to generate aggregation-nuclei, as evidenced by a lag phase like 
period (Fig. 4A). The more extensive growth phase and higher intensity of ThT binding by apo S100A6 also 
suggests higher levels of fibrillization. In fact, this was corroborated by TEM analysis which showed a 
higher fibril content in the apo form, whereas the presence of Ca2+ mainly yielded amorphous aggregates 
(Fig. 4, B–E). Analysis of the aggregated species obtained after 28 days of incubation showed mostly large 
amorphous aggregates have formed (Fig. 4B), independently of the presence of Ca2+ (Fig. 4D). Extending 
the incubation for 65 days resulted in increased fibrillogenesis: long fibrils were detected (Fig. 4C), 
although aggregates were still the most abundant species. Such fibrils were negligible in the presence of 
Ca2+ (Fig. 4E), revealing that Ca2+ refrains fibril formation and leads essentially to the formation of small 
aggregates. These results indicate that also under physiological conditions Ca2+ perturbs the formation of 
S100A6 amyloid fibrils by favoring off pathway oligomers at the expenses of fibrillization competent 
species. The morphological properties of apo S100A6 fibrils produced over longer time scales were 
analyzed in more detail by TEM (Fig. 5). Continued incubation at 37 °C for 84 days resulted in abundant 
fibril formation. In contrast to the acidified preparations, we did not observe various fibril types: the 
preparation became very homogenous and prominent 7–8 nm wide fibrils were present (Fig. 5A). After 
extended incubation for 116 days, the fibrils started to form bundles (Fig. 5B) accompanied by additional 
intertwining and tangling.  
 
 
 
 
Toxicity of S100A6 Oligomers and Fibrils 
S100A6 is a predominantly intracellular protein but also exerts an extracellular action via binding and 
subsequent activation of the receptors for advanced glycation endproducts (RAGE), a pattern recognition 
receptor (15, 34). Considering the new amyloidogenic properties of S100A6 and the fact that insoluble 
protein aggregates are frequently associated with toxic gains of function and cellular toxicity, we have 
thus investigated the toxicity of S100A6 oligomers and fibrils. For this purpose we used the human 
neuroblastoma SHSY-5Y cell line as a model system: upon challenging these cells with different S100A6 
conformers (native protein, oligomers, and amyloid fibrils), cell viability was determined by the WST-1 
reduction assay. Also, considering the inhibitory effect of Ca2+ toward amyloidogenesis, the toxicity of apo 
and Ca2+-bound proteins was compared. Under the conditions assayed, native S100A6 was not toxic, 
regardless of the presence of Ca2+ (Fig. 6). However, a significant toxicity is associated with amyloidogenic 
oligomers obtained at the earlier stages of the growth phase (40% decrease in cell viability). Cellular 
toxicity decreases upon subsequent fibril maturation: late oligomers still result in a 15% decrease in cell 
viability but fibrils have no cytotoxic effect. Interestingly, the aggregated species formed in the presence 
of Ca2+ within all tested growing phases had no effect on cell viability, showing that these aggregates are 
largely distinct from the amyloidogenic ones formed in its absence.  
 
 
S100A6 Seeds SOD1 Fibrillization 
The formation of S100A6 amyloidogenic oligomers and fibrils might represent a novel mode of S100 
mediated central nervous system damage. In fact, the brain of healthy individuals contains protein 
inclusions called corpora amylacea, whose nature is quite unclear, and which contain different S100 
proteins, including S100A6 (35). However, protein depositions can also feature pathologic hallmarks in 
several neurodegenerative human diseases (36). These pathologic aggregates contain a broad mixture of 
distinct proteins, and are not strictly formed by the protein that is generally associated with the resulting 
disease. Coincidently, S100A6 is overexpressed in astrocytes closely associated to degenerating motor 
neurons in ALS patients, where SOD1 enriched cytoplasmic inclusions in are found (11). Although there 
are no reports of S100A6 being found within these ALS-associated aggregates, the overexpression of 
S100A6 in ALS models provides a rationale for investigating cross-seeding phenomena between these two 
proteins.  
To test this possibility, we have implemented an aggregation assay based on apo SOD1, the form which is 
believed to be involved in the onset of ALS pathologic aggregation events. In this assay, carried out at pH 
7 and 37 °C, the aggregation kinetics of apo SOD1 was monitored by ThT fluorescence emission. Under 
these conditions, after a lag phase of 45 h, SOD1 aggregation followed a sigmoidal kinetics with a steady 
state phase reached after 80 h (Fig. 7). Remarkably, a clear seeding effect occurs when aggregation takes 
place in the presence of 2% apo S100A6, where the lag phase substantially decreases down to 31 h. 
S100A6 oligomers have an identical effect. When SOD1 was omitted, no ThT signal variation was 
measurable. These results suggest that S100A6 can potentiate SOD1 aggregation by favoring the 
formation of SOD1 amyloid growth nuclei. Eventually, recruitment of astrocytes to the damaged ALS 
motor neurons resulting in the buildup of S100A6 might trigger interactions between proteins in the 
complex setting of the synapse (36), especially considering the ability of SOD1 aggregates to propagate in 
a prion-like manner in neuronal cells (37).  
 
DISCUSSION 
Here we report the ability of the S100A6 cytokine to form amyloid oligomers and fibrils, in a metal ion 
dependent way, under physiological conditions. S100A6 is a rather stable protein at neutral pH and like 
other proteins has evolved to minimize its self-aggregation propensity (38, 39). In agreement, 
computational analysis evidenced a low overall aggregation propensity throughout the S100A6 sequence. 
Nevertheless, we have collected data showing that transiently populated conformations arising through 
native state fluctuations can underpin its conversion into amyloid prone conformers. Indeed, significant 
aggregation hotspots mapped at helices HI and HIV within the hydrophobic core. These are involved in 
inter-subunit contacts for dimer formation and, unlike helices HII andHIII, do not undergo substantial 
conformational changes upon metal binding (40). We thus hypothesize that S100A6 hydrophobic core 
remodeling yielding amyloid-prone conformers and weaker inter-dimer interactions is an early step in 
S100A6 fibrillar aggregation. In fact, the importance of dimerization as an amyloidogenic protection 
mechanism has been highlighted in the S100A8/A9 heterodimer (6), where the overall aggregation 
propensity of the individual subunits decreases upon heterodimer formation. In agreement, under acidic 
conditions S100A6 does not unfold but undergoes a series of structural rearrangements, resulting in the 
buildup of amyloid prone species which directly nucleate aggregation and eliminate a lag phase. At neutral 
pH, these amyloidogenic intermediate conformations are not readily populated explaining the broadened 
period of time before nucleation occurs. Also, the absence of a well-defined lag phase suggests a 
significant aggregation propensity of S100A6 conformers, without the need for destabilizing (i.e. non-
physiological) conditions to potentiate the aggregation. The aggregation of destabilized (yet native-like) 
folded globular proteins has been suggested as one of the most relevant mechanisms underlying 
amyloidogenesis onset, as it does not involve crossing the major energy barrier of unfolding (41). 
Regarding the cellular effects of these species, the fact is that toxicity induced by native S100 proteins is 
somehow established in the literature. For example, S100B is known for its concentration-dependent 
cellular effects in the central nervous system, being neurotrophic at nanomolar levels (42) and inducing 
apoptosis in a RAGE-dependent manner (43) and exacerbating Aβ neurotoxicity (44) at micromolar 
concentrations. Following the identification of physiological conditions under which S100A6 forms 
amyloid fibrils we then moved to inspect the cytotoxicity of these species in particular. We have observed 
that S100A6 oligomers, and to a lesser extent fibrils, but not native S100A6, affect cell viability. These 
observations agree with the reported observation that amyloid precursor oligomers are cytotoxic species 
(45). Specifically, in AD, cognitive impairment is associated with oligomeric Aβ buildup rather than with 
senile plaque formation. The novelty in our results is the description of increased toxicity associated solely 
with the amyloid conversion of S100A6. The fact that S100A6 overexpression co-localizes with affected 
motor neurons in ALS patients (11, 17) prompted us to check its effects on SOD1, another protein involved 
in this neurodegenerative disease. The observed seeding hints on a putative role of S100A6 in ALS, by 
propagating pathological SOD1 aggregation. In fact, it is established that S100B oligomers interact with 
RAGE receptors, which in turn have also the ability to interact with amyloids (46). S100 proteins are 
actually found in protein inclusions called corpora amylacea in brain tissue, but, so far, never in association 
with disease states. It remains to be shown whether the observations reported here are also true for other 
S100 proteins. This might open a deeper understanding of the role of S100 proteins in different human 
disorders.  
Indeed, complex interactions between amyloidogenic proteins are likely to play a role in 
neurodegenerative processes. Interactions between amyloidogenic proteins, similar to the cross-seeding 
effect herein described for S100A6 and SOD1 have been previously described in the literature, although 
sometimes with distinct features. In Alzheimer disease, the most characteristic neuropathological 
hallmarks are the extracellular Aβ plaques and the intracellular neurofibrillary tangles (NFTs), mostly 
composed by hyperphosphorylated tau protein. Although most cognitive impairment symptoms can be 
recapitulated by tau aggregation alone, co-aggregation of Aβ in a mouse-model contributes to faster NFT 
formation, especially in limbic structures, particularly susceptible to NFT-associated lesions (47). Similarly, 
injection of Aβ1–42 fibrils in P301L mutant tau transgenic mice caused a 5-fold increase in NFT number in 
the cell bodies of neurons projecting into the injection sites (48). Although a physical interaction between 
Aβ and tau was not unequivocally demonstrated, a direct interaction in vivo and in vitro between APP and 
tau, mediated by the Fe65 adaptor protein, was presented (49). Still, N-terminal tau fragments, but not 
the full-length protein, bind to Ab1–42 in the synapse (50). The cellular prion protein (PrPC) has also been 
identified as a mediator of Aβ-induced neuronal degeneration in vivo by functioning as a cell-surface 
receptor binding oligomeric Aβ with nanomolar affinity (51). Supporting this hypothesis, insoluble prion 
protein has been co-purified with forms of Aβ1–42 from human Alzheimer disease brain extracts and 
proposed to be a major Aβ interactor (52). In addition, PrP is expressed in endothelial cells, binds Aβ1–40 
and mediates transcytosis of the peptide through the blood-brain barrier (53). PrP co-deposits within 
amyloid core plaques, although neither Aβ or APP co-precipitate with PrP (54). Furthermore, the co-
localization of PrP with α-synuclein deposits may indicate that PrP is involved in a general cell stress 
response toward protein aggregation (55). Along these lines, it has been recently demonstrated that PrPC 
is required for Aβ oligomer-induced neuronal cell death (56). Despite the above mentioned examples, the 
interaction between amyloidogenic proteins is not always associated with enhanced aggregation. Amyloid 
cross-seeding between Aβ and amylin (57), a peptide hormone co-secreted with insulin from pancreatic 
β-cells, may underlie the positive association between Alzheimer disease and diabetes mellitus type II 
(58), a pathology in which amylin forms amyloid deposits within the pancreas. Nevertheless, non-
amyloidogenic amylin conformers are also competent toward Aβ1–40 binding and redirect Aβ aggregation 
toward non-toxic species by shielding Aβ β-sheets from the solvent and driving non-toxic amylin-Aβ co-
precipitation (59,–,61). The feasibility of both pro-and anti-aggregation effects is supported by the 
presence of the soluble forms of both peptides in blood and the cerebrospinal fluid (62), high APP levels 
in pancreatic extracts (63), presence of hyperphosphorylated tau and aggregated Aβ in Langerhans islets 
in type 2 diabetes patients (63) as well as co-localization of Aβ and amylin islet amyloid deposits (63).  
Extracellular circulating proteins are also involved in amyloidogenic phenomena. Serum amyloid P (SAP) 
and heparan sulfate proteoglycans (HSPG) co-aggregate in many pathological amyloid deposits (e.g. (64,–
,67)) and have been implicated in amyloidogenesis. HSPG associate with amyloid precursors, promote 
misfolding and stabilize nascent fibrils (68, 69). As an example, SAP deposits on the surface of Aβ1–40 fibrils, 
but not protofibrils, in vitro but only in the absence of Ca2+ (70). In accordance, anti-SAP immunization 
leads to SAP deposit clearance (71). Also, SAP enhances amyloid A deposition in mice (72) and, together 
with HSPG, is part of the amyloid fibril core (73, 74). HSPG mediate Aβ binding to the surface of neurons 
and are involved in its uptake (75), a factor contributing to Aβ cytotoxicity. Altogether, these reports 
illustrate the extensive regulation of protein aggregation in disease, as well as the importance of non-
protein components, as suggested by our results.  
The strong effect of Ca2+ on the aggregation of S100A6 suggest an important role of this metal ions in the 
process. Indeed metal ions such as calcium, zinc, and copper are known to play an important role in the 
process of neurodegeneration also as a result of their interaction with protein oligomers. Briefly, metal 
ion binding affects protein dynamics, folding and stability and one of their modes of action is by 
establishing intermolecular interaction critical for the formation of multimeric aggregates. This has been 
observed to occur in many proteins involved in aggregation disorders and this subject has been 
extensively addressed in a recent review to which the interested reader can refer to (36). The 
conformational changes brought about by Ca2+ binding to S100A6 provide the structural background to 
rationalize how its binding modulates amyloid formation. Ca2+ binding to S100A6 results in remodeling of 
surface electrostatics with hydrophobic patch exposure, especially within the aggregation hotspot at helix 
HIV (40). S100A6 oligomers formed in the presence of Ca2+, which feature anti-parallel β-sheets and 
decreased α-helix content at the onset of aggregation, are thus off-pathway species in respect to the 
amyloid fibril forming route. Chelation of Ca2+ reverted these structural changes and restored the stability 
of the S100A6 dimer, shielding the otherwise exposed hydrophobic patches within the core helices. The 
possibility that hydrophobic core remodeling determines and rate limits S100A6 amyloid fibril formation, 
may have broader implications within the S100 protein family.  
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